Sutura Inc. (fka SUTU)

[sayheydave]

SUTU...went fishing and hooked a few shares near closing...news today was carried by Reuters and was totally awesome!

[THE--EAGLE]

correction: the last insider buying was around 8m shares NOT half million. my bad. the company also have $750k cash. with $23m from Abbott the company has around $24m in cash. they have seven patents...49 employees. .09 sp is very cheap IMO.

[rstar]

3yr chartdaily/weekly:

[THE--EAGLE]

yes I guess. now time to move up :))

enjoy

[Stock Stallion]

last hour should be a good one....hope everyone loaded up!

[papadedavid]

Yep...but we hadn't a 0,08 cents ps settlement yesterday...Can't understand it, this should be at 0,14 at least (at the very least I'd say).

[abbytraderwin]

Gap was from .055!

Enjoy

[Go_Stocks]

Very interesting quick drop, bought small 0.095.

[Stock Stallion]

Load them up here!

[abbytraderwin]

Gap from this morning closing?

Enjoy

[jagram]

What the hell just happened??

[GordonGecko]

good point. Need more DD on this one. But sure looks promising !! GOOD LUCK TO YOU :)

[Stock Stallion]

oh it will go....they shook it out now the smart money is entering here.

[dijeetyet]

looks like you might be right about that afternoon run

[Stock Stallion]

the stall is due to certain brokers like aturd restricting online buying....a good sign to me after GREAT NEWS. brokers trying to slow the MOMO of this morning. IMO this is a great place to buy because they will run it this afternoon. this one has a long way to go UP! just cooling off :)

[papadedavid]

Don't know what's going on...but I doubt they need money. They just got 23 MM $...Today only 100k in play....???

[GordonGecko]

haven't watched the L2 closely on this one but I think the company needed some money and raised capital with today's PR.. :/ Saw VFIN on the offers....could mean nothing or could mean something. Nevertheless, with today's news we got a precent for future cases if there are any planned. -Gecko

[THE--EAGLE]

havent done a proper DD yet. but I am quite suprised to see sp stalling here after todays news. I was expecting to see high 20s today. i was wrong I guess. will wait and see. GL

[GordonGecko]

nice...do u kno if there are other infringers out there??? What is the company planning next????? :) TY

[THE--EAGLE]

OS is 271m, insiders hold over 50%. Institutional holding is 27% per Reuters.
Also there was insider buying last week (500K shares).

[pwrballl]

Saw the POP...but after doing the #'s... the BASE! value of SUTU is only .08! 23MM award negated by a BLOATED! OS(~271MM..10Q). Wayyyy OVERPRICED! at this point.

GLTA!!

[GordonGecko]

ahh looks like VFIN offering here ;(

[GordonGecko]

Anyone knows the outstanding on this one? If they are other infringers this thing could be headed much higher....Winning against ABOTT IS HUGE..setting a precedent for any other potential infringers...Reminds me of PTSC from pennies to dollar....... -Gecko

[Leonard1221]

is this a case of premature jumping in, showing weakness?

[klimt]

Marry Christmas SUTU! I just got in at .16...

[sons]

Thanks, I agree!!

[Stock Stallion]

think it will rest a bit then take off again....cross lic with abbott and the 23 mil settlement makes for a nice bottom line for SUTU. I am hoping to see this much higher then .22...would like to see us in the high .20's- low 30's today and then a slow steady growth in PPS over the weeks ahead. this is BIG for a pinky IMO

[sons]

Hey legal, got some at .12 this morning, where do you see this heading? TIA

[Stock Stallion]

yep i grabbed it premarket....its a money maker from here :)

[MWM]

Sutura Settles Patent Infringement Lawsuit With Abbott Laboratories
Sutura, Inc. ("Sutura") (OTCBB: SUTU), a California-based medical device company, announced today that it has settled a patent infringement lawsuit it had against Abbott Laboratories. The settlement provides for a cross license of the Hathaway patents, licensed to Abbott by Indiana University, and the Sutura Nobles patents. In addition, Abbott has agreed to pay Sutura $23 million as part of the settlement agreement.

"We are pleased to have reached this agreement with Abbott and resolved this patent infringement dispute with them," said David Teckman, President and CEO of Sutura. "We now look forward to moving on with our continued enhancement of Sutura's product line of vascular suturing devices, in particular the Sutura EL device."

[Stock Stallion]

looking good for a move today!

[Stock Stallion]

SUTU (.08) Sutura Continues Successful Human Trials of SuperStitch EL in Multiple Human Procedures to Suture PFO's

Monday, October 22 2007 8:34 AM, EST Market Wire "US Press Releases "
FOUNTAIN VALLEY, CALIFORNIA -- (MARKET WIRE) -- 10/22/07 -- Sutura, Inc. ("Sutura") (OTCBB: SUTU), an innovative developer of minimally invasive vascular suturing devices, today announced the successful human use of the SuperStitch EL in three patients to deliver a suture to the septum that separates the left and right atriums of the heart. Dr Michael Mullen placed the sutures into the septum to close defects known as a Patent Foramen Ovale (PFO).
The three successful procedures were performed at the Eskisehir Osmangazi University Hospital in Eskisehir, Turkey by Dr. Michael Mullen, of the Royal Brompton Hospital , London and Dr. Omer Goktekin who interned with Dr. Mullen at Royal Brompton. The SuperStitch EL was placed into the PFO using fluoroscopic and Intra-Cardiac Echocardiography (ICE) guidance (Siemens Cypress system). The suture was placed into the two flaps that make up the septum and then drawn together. The patients had all previously suffered strokes from their PFO's.
Dr. Mullen commented, "These cases confirm that we can accurately identify the septal structures and position the suture in each septum. We also made significant advances in the technique and learning curve. With any new procedure developing the technique is as critical as developing the system. These cases and the follow up results of the case in Georgia demonstrate that we can place a suture in the secundum and primum septums and close a PFO. The significance to the treatment of Structural Heart Disease is immense; now we are able to close a PFO without implanting a mechanical device into the heart, and eliminate the need for lifelong medication regiments."
Dr. Goktekin commented, "This was an exciting and unique opportunity for myself and our institution to participate in what will be a historical advance in cardiology." Dr. Goktekin added, "One of the greatest advantages of this technology is the ability to perform the procedure and not suffer the complications associated with device placement."
Also present for the case was Dr. Anthony Nobles, Chief Scientific Officer at Sutura. "We are honored to work with such a great team and it was the perfect environment to expand our clinical experience," noted Nobles. "We incorporated several improvements learned from our initial experience in Tbilisi and they performed beyond our expectations. Additionally, we substantially improved our learning curve on the deployment and imaging which will allow us to bring this product to market."
Dave Teckman, Sutura's President and CEO added, "This is a significant step to changing the gold standard of leaving a device of any kind behind after the procedure. We believe in time this will eliminate the need for these invasive technologies and mark the introduction of a new era in the treatment of structural heart disease. Accomplishing this is a primary goal of ours at Sutura."
About Sutura, Inc.
Sutura®, Inc. (www.suturaus.com) is a medical device company that has developed a line of innovative, minimally invasive, vascular suturing devices to suture the puncture created in arteries during open surgery and catheter-based procedures. The Company's line of SuperStitch medical devices provide sutured closure of the arteriotomy site utilizing the existing catheter sheath introducer or cannula during fluoroscopically guided procedures and directly through the open arteriotomy during open surgical procedures.
Within the United States the 8F & 6F SuperStitch devices are available for use in performing vascular stitching in general surgery, including endoscopic procedures. It is not intended for blind closure of an arteriotomy site. The SuperStitch 8F & 6F is approved in the European Union and CE marked with the indication for use as follows: The SuperStitch is indicated for use in performing vascular stitching in general surgery, including endoscopic procedures. In the EU there is no requirement for the use of fluoroscopic guidance. Sutura's headquarters are in Fountain Valley, California . "Sutura®" and "SuperStitch®" are registered trademarks of Sutura, Inc.
Forward-Looking Information Is Subject to Risk and Uncertainty
Certain statements in this press release may contain projections or "forward-looking" information (as defined in the Private Securities Litigation Reform Act of 1995) that involve risk and uncertainty. The words "aim", "plan", "likely", "believe", "expect", "anticipate", "intend", "estimate", "will", "should", "could", "may", "appears", and other expressions that indicate future events and trends identify forward-looking statements. These statements are not guaranties of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what we express or forecast in these forward-looking statements. As a result, these statements speak only as of the date they were made and we undertake no obligation to publicly update or revise any forward-looking statements. Our actual results and future trends may differ materially from our forward-looking statements depending on a variety of factors including the ability of the company to raise additional funds necessary for the continued operation of the company, acceptance of the SuperStitch® and HeartStitch® devices by medical providers and the marketplace in general, the ability of the company to establish a successful strategic relationships or to complete strategic transactions with third parties, the continued growth of the vessel closure marketplace and the company's ability to continue to expand and protect its technology patents.
Contacts:
Sutura, Inc.
Barry Forward
Corporate Communications
1-866-676-8386
Website: www.suturaus.com